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Purpose
To identify host and tumor factors which predict a com-
plete pathologic response (pCR) after neoadjuvant treat-
ment with cisplatin chemotherapy in women with breast
cancer and a BRCA1 mutation.
Patients and methods
50 women with breast cancer and a BRCA1 mutation,
who presented with stage I to III breast cancer between
December 2006 and April 2010 were enrolled and trea-
ted with cisplatin 75 mg/m
2 every three weeks for four
cycles, followed by mastectomy and conventional che-
motherapy. Eight patients had prior chemotherapy for a
previous cancer diagnosis. Three patients received prior
chemotherapy for their current cancer diagnosis but
received protocol therapy and thus were followed for
toxicity and evaluated for response. Information was
collected on clinical stage, grade, hormone receptor sta-
tus and Her2neu (HER2) status prior to treatment.
Pathologic complete response was determined by review
of surgical specimens.
Results
47 patients were enrolled in the study, including 39
patients for whom this was the first primary breast can-
cer and who had no previous chemotherapy and 8
patients who had previously received chemotherapy. A
pathologic complete response (pCR) was observed in 34
patients (68%) including 82% of women who had no
previous chemotherapy and 18% of women who had
previously received chemotherapy.
Conclusions
Platinum-based chemotherapy is effective in a high pro-
portion of patients with BRCA1-associated breast can-
cer, but may be less effective in women who have been
previously been treated with another form of
chemotherapy.
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